Actively Recruiting
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Led by Uppsala University · Updated on 2024-11-29
100
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
Sponsors
U
Uppsala University
Lead Sponsor
U
Uppsala County Council, Sweden
Collaborating Sponsor
AI-Summary
What this Trial Is About
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.
CONDITIONS
Official Title
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of first relapse after previous ASCT for multiple myeloma according to the International Myeloma Working Group.
- Treated with a second ASCT (ASCT2) as part of second line treatment at UUH.
- Conditioning at ASCT2 with bortezomib-bendamustine-melphalan or high-dose melphalan only.
You will not qualify if you...
- Double (tandem) ASCT in first or second line treatment
- Allogenic haematopoietic stem cell transplantation as part of first or second line therapy
- Failure to meet the minimal dataset, defined as: (date of ASCT1 and ASCT2, date of start of induction treatment for relapsed myeloma prior to ASCT2, medical records from hospitalization for ASCT2, at least one follow-up visit (unless early death before first follow-up visit), date of progression and first treatment of relapsed multiple myeloma after ASCT2.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Akademiska sjukhuset
Uppsala, Sweden
Actively Recruiting
Research Team
T
Thomas Silfverberg, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here